IM Cannabis Q1 Revenue CAD 8.7M; Net Loss CAD 2.5M; G&A Down 22%
In Q1 ended March 31, 2026, IM Cannabis reported CAD 8.7 million in revenue, CAD 1.4 million gross profit, a CAD 1.7 million operating loss and CAD 2.5 million net loss. The company cut G&A expenses 22% y/y and raised liquidity through convertible notes to fund cost optimization initiatives.
1. Q1 2026 Financial Performance
For the quarter ended March 31, 2026, IM Cannabis recorded revenues of CAD 8.7 million and gross profit of CAD 1.4 million. The period yielded an operating loss of CAD 1.7 million and a net loss of CAD 2.5 million.
2. Cost Optimization and Liquidity Management
The company reduced general and administrative expenses by 22% year-over-year through streamlined operations and expense controls. It also completed convertible note financings during the quarter and after quarter-end to strengthen working capital and support ongoing cost optimization.
3. Management Outlook and Strategic Focus
Management remains committed to operational efficiencies, disciplined working capital management and the evaluation of strategic opportunities to drive long-term growth across its medical cannabis platforms in Israel and Germany.